Patents Assigned to Formosa Laboratories Inc.
  • Method of preparing ferric carboxymaltose
    Patent number: 11731998
    Abstract: Provided is a method of preparing ferric carboxymaltose with weight average molecular weight between 100,000 and 400,000. The method includes reacting an oxidized maltodextrin solid with an iron (III) salt solution in acidic and basic conditions in sequence to afford ferric carboxymaltose, wherein the oxidized maltodextrin solid has a dextrose equivalent of less than 4. The ferric carboxymaltose prepared by the method can withstand high-temperature sterilization with high stability and facilitate storage.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: August 22, 2023
    Assignee: FORMOSA LABORATORIES, INC
    Inventors: Rung-Tian Suen, Yao-Ting Wang, Keng-Ming Chang, Ming-Kuang Hsu
  • METHOD OF PREPARING FERRIC CARBOXYMALTOSE
    Publication number: 20230052476
    Abstract: Provided is a method of preparing ferric carboxymaltose with weight average molecular weight between 100,000 and 400,000. The method includes reacting an oxidized maltodextrin solid with an iron (III) salt solution in acidic and basic conditions in sequence to afford ferric carboxymaltose, wherein the oxidized maltodextrin solid has a dextrose equivalent of less than 4. The ferric carboxymaltose prepared by the method can withstand high-temperature sterilization with high stability and facilitate storage.
    Type: Application
    Filed: January 20, 2022
    Publication date: February 16, 2023
    Applicant: FORMOSA LABORATORIES, INC
    Inventors: Rung-Tian SUEN, Yao-Ting WANG, Keng-Ming CHANG, Ming-Kuang HSU
  • Crystalline of camphorsulfonic acid salt of rucaparib and method of preparing of tricyclic compounds, rucaparib and crystalline of camphorsulfonic acid salt of rucaparib
    Patent number: 11021483
    Abstract: A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R1 is H or a C1-3 alkyl group; and R2 is H, a halogen element or a C1-3 alkyl group.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: June 1, 2021
    Assignee: Formosa Laboratories, Inc.
    Inventors: Wen-Chieh Yang, Mei-Jing Lee, Hsueh-Chen Lee, Lung-Hsiang Li
  • Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
    Patent number: 10766900
    Abstract: The present disclosure provides a Baricitinib intermediate, a method for preparing the Baricitinib intermediate, and a method for preparing Baricitinib or a pharmaceutically acceptable salt thereof using the Baricitinib intermediate. The method for preparing the Baricitinib intermediate involves the use of a divalent palladium catalyst or a nickel catalyst and provides the Baricitinib intermediate in high yield.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: September 8, 2020
    Assignee: FORMOSA LABORATORIES, INC.
    Inventor: Hsiang-Yun Lai
  • Polymorph of pazopanib hydrochloride and preparation process thereof
    Patent number: 10626110
    Abstract: The present disclosure provides a crystalline form F of Pazopanib HCl, which is characterized by an X-ray diffraction (XRD) pattern having peaks at about 11.3, 14.6, 16.9, 19.5, 19.7, 23.5 and 25.9°±0.2° 2?. The present disclosure also provides a preparation process of a crystalline form F of Pazopanib HCl.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 21, 2020
    Assignee: FORMOSA LABORATORIES, INC.
    Inventor: Sheng-Kai Ko
  • Polymorphs of sugammadex and process for preparation of sugammadex
    Patent number: 10336835
    Abstract: The present invention provides a crystalline form of Suagmmadex sodium, characterized by an X-ray powder diffraction pattern. The present invention further provides crystalline forms of Suagmmadex sodium for use in the manufacture of a pharmaceutical composition or a medicament. The present invention further provides a pharmaceutical composition comprising the crystalline form of Sugammadex sodium of the present invention and at least one pharmaceutical acceptable excipient.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: July 2, 2019
    Assignee: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • Method for preparation of sugammadex sodium
    Patent number: 10233263
    Abstract: The present invention provides a method for improved preparation of Sugammadex sodium.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 19, 2019
    Assignee: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • METHOD FOR PREPARATION OF SUGAMMADEX SODIUM
    Publication number: 20190062459
    Abstract: The present invention provides a method for improved preparation of Sugammadex sodium.
    Type: Application
    Filed: August 23, 2017
    Publication date: February 28, 2019
    Applicant: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • POLYMORPHS OF SUGAMMADEX AND PROCESS FOR PREPARATION OF SUGAMMADEX
    Publication number: 20190062460
    Abstract: The present invention provides a crystalline form of Suagmmadex sodium, characterized by an X-ray powder diffraction pattern. The present invention further provides crystalline forms of Suagmmadex sodium for use in the manufacture of a pharmaceutical composition or a medicament. The present invention further provides a pharmaceutical composition comprising the crystalline form of Sugammadex sodium of the present invention and at least one pharmaceutical acceptable excipient.
    Type: Application
    Filed: August 23, 2017
    Publication date: February 28, 2019
    Applicant: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • Preparation of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids
    Patent number: 10023603
    Abstract: The present invention provides preparations of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids. The present invention also provides novel monosaccharides, disaccharides, trisaccharides and pentasaccharides for use in the preparation of heparinoids.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: July 17, 2018
    Assignee: Formosa Laboratories, Inc.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • METHOD FOR THE PREPARATION OF TERIFLUNOMIDE
    Publication number: 20170073304
    Abstract: The present invention relates to a method for preparation of Teriflunomide, comprising steps of: (a) adding Leflunomide to an alcoholic solvent to give solution (I); (b) adding an aqueous sodium hydroxide solution slowly into the solution (I) to give solution (II); (c) acidifying the solution (II) with inorganic acid for precipitation to give solution (III); and (d) filtering the solution (III) to give Teriflunomide.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 16, 2017
    Applicant: FORMOSA LABORATORIES INC.
    Inventors: CHING-PENG WEI, PEI-CHEN HUANG
  • PREPARATION OF MONOSACCHARIDES, DISACCHARIDES, TRISACCHARIDES, AND PENTASACCHARIDES OF HEPARINOIDS
    Publication number: 20170015695
    Abstract: The present invention provides preparations of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids. The present invention also provides novel monosaccharides, disaccharides, trisaccharides and pentasaccharides for use in the preparation of heparinoids.
    Type: Application
    Filed: March 30, 2016
    Publication date: January 19, 2017
    Applicant: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • Method for preparing nilotinib
    Patent number: 9187452
    Abstract: The present invention provides a method for preparing Nilotinib of the following structure: by direct condensation of an ester and an aniline promoted by trialkyl aluminum in an organic solvent.
    Type: Grant
    Filed: September 7, 2014
    Date of Patent: November 17, 2015
    Assignee: FORMOSA LABORATORIES, INC.
    Inventors: Jui-Te Hung, Wen-Chin Chen
  • CRYSTALLINE FORM OF MAXACALCITOL
    Publication number: 20140051875
    Abstract: The present invention relates to maxacalcitol hydrate, a new crystalline form of maxacalcitol, with superior technical properties e.g. in the manufacture of crystal suspension formulations, and with superior stability properties.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 20, 2014
    Applicant: FORMOSA LABORATORIES INC.
    Inventors: CHING-PENG WEI, PEI-CHEN HUANG
  • METHOD FOR PREPARING POLY(ALLYLAMINE) HYDROCHLORIDE AND DERIVATIVES THEREFROM
    Publication number: 20130123433
    Abstract: The present invention provides a method for preparing poly(allylamine) hydrochloride, sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride. The present invention also relates to a process for preparing oly(allylamine) hydrochloride, sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride with low allylamine content and high specific gravity.
    Type: Application
    Filed: November 14, 2011
    Publication date: May 16, 2013
    Applicant: FORMOSA LABORATORIES, INC.
    Inventors: YU-LIANG LIU, CHING-PENG WEI
  • Compounds and preparation for montelukast sodium
    Patent number: 8399675
    Abstract: This invention relates to novel compounds and a process for preparation of montelukast sodium.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: March 19, 2013
    Assignee: Formosa Laboratories, Inc.
    Inventors: Jui-Te Hung, Ching-Peng Wei
  • PROCESS FOR PREPARING HIGH PURITY 1alpha-HYDROXY VITAMIN D2
    Publication number: 20120108554
    Abstract: The present invention relates to a process for purifying Doxercalciferol, a synthetic vitamin D analog, also known as 1?-hydroxy vitamin D2, to the purity greater than 99.5% by crystallization from a mixed solvent of methanol and acetonitrile. Each of the individual impurities can be controlled no more than 0.1% which meets the individual unknown impurities specification requirement of International Conference on Harmonisation (ICH) guideline. The crystallization yield is more than 75% which is suitable for employed as a commercial process.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 3, 2012
    Applicant: FORMOSA LABORATORIES, INC.
    Inventors: Bang-I Liou, Ching-Peng Wei
  • PROCESS FOR PREPARING TEMOZOLOMIDE
    Publication number: 20120108811
    Abstract: This present invention provides an improved process for preparing Temozolomide (TMZ) stable at room temperature for at least 18 months. This present invention also relates to Temozolomide stable at room temperature for at least 18 months.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 3, 2012
    Applicant: FORMOSA LABORATORIES INC.
    Inventors: Mei-Jing Lee, Ching-Peng Wei
  • Paricalcitol intermediates
    Patent number: 8026379
    Abstract: The present invention relates to a compound and a novel process for the preparation of Paricalcitol intermediates.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: September 27, 2011
    Assignee: Formosa Laboratories, Inc.
    Inventors: Chze-Siong Ng, Ching-Peng Wei
  • PREPARATION OF PARICALCITOL
    Publication number: 20110137058
    Abstract: This invention relates to a method for purifying Paricalcitol by reverse phase chromatography. This invention also relates to a purified Paricalcitol prepared by said method. This invention further relates to a method for purifying Paricalcitol by crystallization.
    Type: Application
    Filed: February 15, 2011
    Publication date: June 9, 2011
    Applicant: FORMOSA LABORATORIES, INC.
    Inventors: CHZE-SIONG NG, CHING-PENG WEI